PARP抑制剂应用后的卵巢癌三级预防  

Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy

作　　者：臧荣余[1] ZANG Rongyu(Department of Gynecologic Oncology,Ovarian Cancer Center,Zhongshan Hospital,Fudan University,National Medical Center,Shanghai 200032,China)

机构地区：[1]国家医学中心,复旦大学附属中山医院妇科肿瘤科,复旦大学附属中山医院卵巢癌临床中心,上海200032

出　　处：《肿瘤防治研究》2023年第2期109-112,共4页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(82273388,81972429);上海市科委医学创新研究专项(22Y21900300)。

摘　　要：当下卵巢癌第三级预防的主要任务:患者全生命周期的管理和关怀;患者的初诊教育和培训;合格外科手术医生的培训;PARPi使用后生物学行为的再认识。手术仍然是卵巢癌治疗的基石,PARPi使用后的复发卵巢癌手术需谨慎对待。美国FDA新近撤回了PARP抑制剂治疗L3+化疗后复发卵巢癌的适应证,因为这三种PARPi增加30%以上的卵巢癌患者死亡风险。现有情况下,我们需要重点关注PARPi后的生物学复发和PARPi导致的耐药,尤其是复发后生存时间的改变。The tertiary prevention approaches of ovarian cancer include whole-person care,training of the patients to cooperate with physicians in the periods of treatment and follow-up,training program of the qualified surgeons,and recognition of biological behavior changes of relapse after PARPi therapy.Surgery remains the cornerstone in the management of ovarian cancer,but the role of surgery after PARPi remains unknown.Recently,the US FDA withdrew the indication of three PARP inhibitors in the treatment of recurrent ovarian cancer with≥3 lines of chemotherapy because of their≥30%increased death risk.Thus,we should pay more attention to the biological recurrence and chemoresistance caused by PARP inhibitors and post-progression survival in ovarian cancer.

关 键 词：卵巢癌 三级预防 PARP抑制剂 耐药 

分 类 号：R737.31[医药卫生—肿瘤]